- Patients
- Clinical Research
- Clinical trials
- AAA617-Lu-Prostate
Prostate Cancer
AAA617-Lu-Prostate
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
Trial overview
Theranostics
Prostate |
III
Cabrini (Gandel Wing)
Cabrini Hospital Malvern, Level B4, Gandel Wing, 183 Wattletree Road, Malvern, VIC, 3144, Australia
(03) 9597 6900 cabrinireception@genesiscare.comRadiation Oncologist
A/Prof. Michael Ng
MBBS (Hons), FRANZCR
St Vincent's Melbourne (Oncology) +2
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.